Seminal Study Details Published in Ophthalmic and Physiological Optics,
Affirming CooperVision Myopia Control Leadership
SAN RAMON, CALIF., December 12, 2023—CA new peer-reviewed paper has further validated the myopia control efficacy of CooperVision’s innovative MiSight® 1 day contact lenses. Published in Ophthalmic and Physiological Optics, the journal of the UK College of Optometrists, Six-Year Cumulative Treatment Effect and Treatment Efficacy of a Dual Focus Myopia Control Contact Lens (Chamberlain P, et al) details findings and insights from the groundbreaking study—the longest investigation of its kind. The paper is available via open access at https://doi.org/10.1111/opo.13240.
In addition, the company has released a companion video interview with two of the paper’s co-authors and CooperVision R&D leaders: Senior Director of Research Programs Paul Chamberlain, BSc (Hons) and Research Fellow Arthur Bradley, PhD. Hosted by Myopia Profile’s Kate Gifford, PhD and Paul Gifford, PhD, it describes the study methodologies, outcomes, and clinical applications. The video can be viewed at Myopia Profile.
“We remain committed to provide eye care professionals with high quality evidence to answer important questions on the long-term impact of myopia management with MiSight® 1 day” said Chamberlain, CooperVision. “The rigorous, multi-center study design, unequaled investigation timeframe, and clear outcomes have strengthened prescribing confidence for this unique, effective optical intervention to slow the progression of myopia. This publication will further reinforce those evidence-based behaviors, as the global eye care community collectively addresses the childhood myopia epidemic.”
The paper describes that in the absence of a second phase control group for ethical reasons, prior myopia progression, emmetropic eye growth, and delay in time to progress analysis methods can be used to estimate myopia control efficacy. MiSight® 1 day slowed eye growth to less than half that observed in untreated children, paralleling modelled rates of emmetropic eye growth. Moreover, when myopic children begin treatment with MiSight® 1 day between the ages of 8-12, the probability of > 0.3mm eye growth occurring within one to three years decreased by 95%.
The paper also confirms the value of pursuing myopia control treatment for young children using MiSight® 1 day. Early intervention provides opportunity for greater myopia control potential, which may help reduce reliance on vision correction, limit changes in prescriptions between appointment visits in support of developmental and educational milestones, lessening myopia’s impact on future ocular health.
Now prescribed in more than 30 countries, CooperVision’s MiSight® 1 day is the first and only soft contact lens approved by the FDA to both correct vision and slow the progression of myopia in children aged 8-12 at the initiation of treatment.1* Additionally, it was the first Chinese NMPA-approved soft contact lens with an indication relating to slowing the progression of axial length in patients who at initiation are 8-12 years old and have a refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of astigmatism. It also has the CE mark designation. The company also offers a range of orthokeratology contact lens designs and spectacle lenses with Diffusion Optics Technology™ for myopia management.**
# # #
U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
China Indications for Use: MiSight® 1 day is indicated for the correction of myopia for patients with non-diseased phakic eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of astigmatism. It has the dual focal design with alternative multiple rings, which allows part of the light passing through the optical zone to focus in front of the retina, forming myopic defocus with the expectation to slow the change of axial length of the patients. Fitting and evaluation of the product should be in medical institutions by ophthalmologists with an intermediate title or above and with regular monitoring. It must be used in strict accordance with the IFU requirements.
‡Compared to a single vision 1-day lens over a six-year period.
‡‡Spectacles with Diffusion Optics Technology™ are not approved for sale or distribution in every country worldwide.
1 Chamberlain, P, Hammond, DS, Arumugam, B, Bradley, A. Six-year cumulative treatment effect and treatment efficacy of a dual focus myopia control contact lens. Ophthalmic Physiol Opt. 2023; 00: 1–7. https://doi.org/10.1111/opo.13240
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com
Media Contact
Mike McDougall, APR, Fellow PRSA, FAAO
McDougall Communications for CooperVision
mike@mcdougallpr.com or +1-585-545-1815
SA10485_1